Inogen reports growth in Q4 and full year 2024 revenue

Inogen, recognized as a global leader in medical technology, focuses on developing and marketing innovative respiratory therapy devices for patients with chronic respiratory conditions. The company's products are widely available through partnerships with patients, prescribers, home medical equipment providers, and distributors. With a gross profit margin of 44.22%, the company demonstrates strong pricing power in its market segment. With a gross profit margin of 44.22%, the company demonstrates strong pricing power in its market segment.

This fiscal growth is attributed to a significant surge in business-to-business revenue, while Inogen continues to focus on stabilizing its direct-to-consumer revenue and enhancing profitability. In 2024, Inogen introduced new products, including Rove 4, and received FDA clearance for the SIMEOX 200 device, expanding its global product offerings. The company maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 2.66, according to InvestingPro analysis.

Kevin Smith, President and CEO of Inogen, expressed confidence in the company's trajectory, emphasizing the return to revenue growth, improved profitability, and disciplined cost management. He highlighted Inogen's commitment to delivering leading devices for patients with respiratory diseases. The market appears to share this confidence, as the stock has delivered an impressive 59.7% return over the past year, despite current profitability challenges. Subscribers to InvestingPro can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of Inogen's financial health and growth prospects.

Inogen will release its official financial results for Q4 and the full year 2024 after the market closes on February 25, 2025. A conference call hosted by Inogen management is scheduled for the same day at 2:00 pm PT / 5:00 pm ET. The call will be available to interested parties via live audio webcast on the Inogen Investor Relations website, with an archived recording accessible for six months.

Inogen, recognized as a global leader in medical technology, focuses on developing and marketing innovative respiratory therapy devices for patients with chronic respiratory conditions. The company's products are widely available through partnerships with patients, prescribers, home medical equipment providers, and distributors.

The information in this article is based on a press release statement by Inogen, Inc.

In other recent news, Inogen Inc (NASDAQ:INGN). reported a 6% year-over-year revenue increase to $89 million in its third-quarter earnings call, driven by a 20% surge in business-to-business sales. Despite a 23.2% decline in direct-to-consumer sales, the medical technology company raised its full-year revenue forecast, now set between $329 million and $331 million, indicating a 4% to 5% growth. It also reported a significant improvement in gross margins to 46.5%.

Inogen launched its new product, the Rove 4 portable oxygen concentrator, and continues its discussions with the FDA regarding Simeox, marking its focus on innovation and market expansion. The company generated $3 million in positive cash flow and reported an adjusted EBITDA of $0.5 million. However, it recorded a GAAP net loss of $6 million, though this was an improvement from the previous year's $45.7 million loss.

These recent developments reflect a company in transition, striking a balance between growth in its business-to-business segment and a restructured direct-to-consumer sales approach. The improved gross margin and positive adjusted EBITDA demonstrate Inogen's move towards profitability. With a strong cash position and no debt, Inogen appears financially stable as it continues to innovate and expand its market reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.